Zacks Investment Research
24 Jun 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Wall Street analysts have a mean price target of $132.25 for Veradermics (MANE), implying a potential upside of 27.7% from its current price of $103.6. — Positive analyst consensus on price targets typically attracts buyers and creates upward pressure on the stock price.
+0.40There is a positive trend in earnings estimate revisions for Veradermics, indicating analysts expect the company to report better earnings than previously estimated. — Upward earnings revisions are a strong fundamental signal that often precedes share price appreciation.
+0.30Which stocks this story touches
The stock has gained value and analysts suggest a potential upside of 27.7% with positive earnings estimate revisions.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
